FI962322A0 - Kristallisk, polymorfisk form av (S,S,S)-N-(1-(2-karboxi-3-(N2-mesyllysylamino)propyl)-1-cyklopentylkarbonyltyrosin - Google Patents

Kristallisk, polymorfisk form av (S,S,S)-N-(1-(2-karboxi-3-(N2-mesyllysylamino)propyl)-1-cyklopentylkarbonyltyrosin

Info

Publication number
FI962322A0
FI962322A0 FI962322A FI962322A FI962322A0 FI 962322 A0 FI962322 A0 FI 962322A0 FI 962322 A FI962322 A FI 962322A FI 962322 A FI962322 A FI 962322A FI 962322 A0 FI962322 A0 FI 962322A0
Authority
FI
Finland
Prior art keywords
polymorphic form
crystalline
mesyllysylamino
cyclopentylcarbonyl
tyrosine
Prior art date
Application number
FI962322A
Other languages
English (en)
Finnish (fi)
Other versions
FI120305B (sv
FI962322A (sv
Inventor
Peter Dunn
Michael Leslie Hughes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI962322A publication Critical patent/FI962322A/sv
Publication of FI962322A0 publication Critical patent/FI962322A0/sv
Application granted granted Critical
Publication of FI120305B publication Critical patent/FI120305B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
FI962322A 1993-12-04 1996-06-03 Förfarande för framställning av en ny, terapeutisk användbar kristallisk, polymorfisk form av (S,S,S)-N-(1-[2-karboxi-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyltyrosin och mellanprodukter använda i förfarandet FI120305B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9324931 1993-12-04
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives
EP9403750 1994-11-09
PCT/EP1994/003750 WO1995015308A1 (en) 1993-12-04 1994-11-09 Crystalline, polymorphic form of (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine

Publications (3)

Publication Number Publication Date
FI962322A FI962322A (sv) 1996-06-03
FI962322A0 true FI962322A0 (sv) 1996-06-03
FI120305B FI120305B (sv) 2009-09-15

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962322A FI120305B (sv) 1993-12-04 1996-06-03 Förfarande för framställning av en ny, terapeutisk användbar kristallisk, polymorfisk form av (S,S,S)-N-(1-[2-karboxi-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyltyrosin och mellanprodukter använda i förfarandet

Country Status (26)

Country Link
US (1) US6180665B1 (sv)
EP (1) EP0731787B1 (sv)
JP (1) JP2701988B2 (sv)
KR (1) KR100203314B1 (sv)
CN (1) CN1068586C (sv)
AT (1) ATE175664T1 (sv)
CA (1) CA2178085C (sv)
CZ (1) CZ296428B6 (sv)
DE (1) DE69416003T2 (sv)
DK (1) DK0731787T3 (sv)
EG (1) EG20562A (sv)
ES (1) ES2128031T3 (sv)
FI (1) FI120305B (sv)
GB (1) GB9324931D0 (sv)
GR (1) GR3029590T3 (sv)
HU (1) HU225959B1 (sv)
IL (1) IL111791A (sv)
MY (1) MY115430A (sv)
NO (1) NO306714B1 (sv)
NZ (1) NZ276087A (sv)
PE (1) PE9296A1 (sv)
PL (1) PL178559B1 (sv)
RU (1) RU2131869C1 (sv)
TW (2) TW534901B (sv)
WO (1) WO1995015308A1 (sv)
ZA (1) ZA949595B (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018217A1 (en) 2000-08-29 2002-03-07 Riverside Forest Products Limited Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
TW434210B (en) 2001-05-16
HU225959B1 (en) 2008-01-28
EP0731787B1 (en) 1999-01-13
CZ296428B6 (cs) 2006-03-15
CN1142816A (zh) 1997-02-12
HUT74683A (en) 1997-01-28
NO962294D0 (no) 1996-06-04
IL111791A0 (en) 1995-01-24
PL178559B1 (pl) 2000-05-31
ES2128031T3 (es) 1999-05-01
US6180665B1 (en) 2001-01-30
GB9324931D0 (en) 1994-01-26
MY115430A (en) 2003-06-30
EP0731787A1 (en) 1996-09-18
PL314794A1 (en) 1996-09-30
CZ160496A3 (en) 1996-11-13
ATE175664T1 (de) 1999-01-15
RU2131869C1 (ru) 1999-06-20
CA2178085C (en) 2002-09-03
KR960706470A (ko) 1996-12-09
HU9601506D0 (en) 1996-07-29
PE9296A1 (es) 1996-04-04
EG20562A (en) 1999-08-30
FI120305B (sv) 2009-09-15
DE69416003T2 (de) 1999-05-27
DK0731787T3 (da) 1999-08-30
GR3029590T3 (en) 1999-06-30
JP2701988B2 (ja) 1998-01-21
AU684114B2 (en) 1997-12-04
TW534901B (en) 2003-06-01
CA2178085A1 (en) 1995-06-08
CN1068586C (zh) 2001-07-18
ZA949595B (en) 1996-06-03
FI962322A (sv) 1996-06-03
KR100203314B1 (ko) 1999-06-15
NO306714B1 (no) 1999-12-13
NZ276087A (en) 1997-11-24
NO962294L (no) 1996-06-04
DE69416003D1 (en) 1999-02-25
IL111791A (en) 2002-09-12
JPH09500654A (ja) 1997-01-21
WO1995015308A1 (en) 1995-06-08
AU8142494A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
FI932229A0 (fi) Azabicykliska bryggderivat
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
BG103485A (en) Ketobanzamides as calpain inhibitors
DK0696281T3 (da) Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
NO963370D0 (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
FI962322A (sv) Kristallisk, polymorfisk form av (S,S,S)-N-(1-(2-karboxi-3-(N2-mesyllysylamino)propyl)-1-cyklopentylkarbonyltyrosin
FI963168A0 (sv) Nya indan-2-merkaptoacetylamiddisulfidderivat användbara som inbibitorer för enkefalinas
KR970701188A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ACE)의 억제제로서 유용한 신규의 머캅토아세틸아미드 디설파이드 유도체(Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ACE)
CA2171972A1 (en) Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: PFIZER IRELAND PHARMACEUTICALS

Free format text: PFIZER IRELAND PHARMACEUTICALS

FG Patent granted

Ref document number: 120305

Country of ref document: FI

MM Patent lapsed